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125REPLY: Left Atrial Appendage
Occlusion Device Societal Overview
The Surgeon’s CommentWhile the American College of Cardiology/Heart
Rhythm Society/Society for Cardiovascular Angiog-
raphy and Interventions (ACC/HRS/SCAI) statement
on left atrial appendage (LAA) occlusion devices
principally focused upon the rapidly evolving tech-
nologies for percutaneous occlusion (1), the principles
stated in the document—including the need for robust
evidence and the importance of multidisciplinary
involvement in decision making—are equally relevant
to surgical and thoracoscopic approaches as described
in the letter from Drs. Emmert and Salzberg.
As the correspondents indicate, several approaches
have been suggested to achieve LAA occlusion.
However, meaningful comparative outcomes data,
both with respect to efﬁcacy and safety for these ap-
proaches, are generally lacking. The published
studies of surgical and thoracoscopic approaches are
uniformly small, performed within few centers, and
do not include comparisons with standard therapy
(which would include no therapy among patients who
cannot tolerate anticoagulation) (2–4). While inter-
esting, the surrogate endpoint of completeness of
LAA closure cannot be assumed to translate into im-
provements in patient outcomes. The current litera-
ture of these alternative approaches does not
establish efﬁcacy in terms of outcomes meaningful to
patients such as stroke or bleeding. Furthermore,
precise estimates of safety among patients for whom
this technology might be used in diverse centers are
not available. The LAAOS III (Left Atrial Appendage
Occlusion Study III) trial is assessing surgical LAA
ligation in a randomized design with a principal
endpoint of stroke (5). Because it will provide
comparative data on safety and efﬁcacy of an
approach to LAA occlusion, the study is unusual and
the results will be informative. However, LAAOS III
will apply only to patients who, similar to those
enrolled in the trial, are undergoing cardiac surgery
for other reasons.
Regardless of the approaches considered for LAA
occlusion, the multisocietal document (1) emphasizes
the need for more informative data for each tech-
nology, including trials to establish efﬁcacy based
upon endpoints important to patients as well as
observational data of approved devices to understandpatient selection, procedural safety, and long-term
outcomes in contemporary practice. These princi-
ples are equally applicable to surgical and thoraco-
scopic approaches. The document (1) also strongly
endorses a multidisciplinary approach to the evalu-
ation and treatment of patients considered for the
use of LAA occlusion devices suggested by Drs.
Emmert and Salzberg. The team involved in this
discussion should invariably include the procedural
specialists who would perform the procedure or
procedures considered for an individual patient.
Thus, in those cases where a surgical approach is
considered, surgeons should naturally be involved
in the discussion. In all cases, these discussions
should be informed by robust data on safety and
effectiveness to support meaningful shared decision
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